Mar 22, 2024 · Emblaveo is an antibiotic used in adults to treat: Complicated (difficult to treat) intra-abdominal (belly) infections; Hospital-acquired pneumonia (an infection of the lungs that is caught during a hospital stay), including ventilator-associated pneumonia (pneumonia that develops in patients who use a machine called a ventilator to help them ...

Apr 22, 2024 · EMBLAVEO ® is the first β-lactam/β-lactamase inhibitor antibiotic combination approved in the European Union for treating serious infections in adult patients caused by multidrug-resistant Gram-negative bacteria, including metallo-β-lactamase-producing bacteria

Aztreonam/avibactam, sold under the brand name Emblaveo (by Pfizer), is a combination of aztreonam, a β-lactam antibiotic, and avibactam, a β-Lactamase inhibitor, developed by AbbVie and Pfizer for aerobic Gram-negative infections.

What is Emblaveo and what is it used for? Emblaveo is an antibiotic medicine that contains two active substances aztreonam and avibactam. Aztreonam belongs to the group of antibiotics called “monobactams”. It can kill certain types of bacteria (so-called Gram-negative bacteria).

Emblaveo is indicated for the treatment of the following infections in adult patients (see sections 4.4 and 5.1): Complicated intra-abdominal infection (cIAI) Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) Complicated urinary tract infection (cUTI), including pyelonephritis

Emblaveo is an antibiotic used in adults to treat: • Complicated (difficult to treat) intra-abdominal (belly) infections; • Hospital-acquired pneumonia (an infection of the lungs that is caught during a hospital stay),

Mar 22, 2024 · If approved, EMBLAVEO® will be indicated for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP) including ventilator-associated pneumonia (VAP), complicated urinary tract infections (cUTI), including pyelonephritis, and infections due to aerobic Gram-negative organisms with ...

Emblaveo is indicated for the treatment of the following infections in adult patients (see sections 4.4 and 5.1): Complicated intra-abdominal infection (cIAI) Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) Complicated urinary tract infection (cUTI), including pyelonephritis

Apr 23, 2024 · The European Commission (EC) has granted marketing authorisation for Pfizer’s EMBLAVEO (aztreonam-avibactam), aimed at treating adults with multidrug-resistant infections where treatment options are limited.

Apr 22, 2024 · Pfizer Inc. (NYSE: PFE) today announced that the European Commission (EC) has granted marketing authorization for EMBLAVEO® (aztreonam-avibactam) for the treatment of adult patients with complicated intra-abdominal infections (cIAI), hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP), and complicated urinary ...